{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:57:16Z","timestamp":1788209836992,"version":"build-2803163510"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM132396"],"award-info":[{"award-number":["R01GM132396"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-21-036-01-TBE"],"award-info":[{"award-number":["RSG-21-036-01-TBE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proteasome inhibitor drugs are currently used in the clinic to treat multiple myeloma and mantle cell lymphoma. These inhibitors cause accumulation of undegraded proteins, thus inducing proteotoxic stress and consequent cell death. However, cancer cells counteract this effect by activating an adaptive response through the transcription factor nuclear factor erythroid 2-related factor 1 (NRF1, also known as NFE2L1). NRF1 induces transcriptional upregulation of proteasome and autophagy\/lysosomal genes, thereby reducing proteotoxic stress and diminishing the effectiveness of proteasome inhibition. While suppressing this protective autophagy response is one potential strategy, here we investigated whether this heightened autophagy could instead be leveraged therapeutically. To this end, we designed an autophagy-targeting chimera (AUTAC) compound to selectively degrade the anti-apoptotic protein Mcl1 via the lysosome. Our results show that this lysosome-mediated targeted degradation is significantly amplified in the presence of proteasome inhibition, in a NRF1-dependent manner. Mechanistically, AUTAC-driven Mcl1 clearance requires K63-linked ubiquitination by UBC13 and TRAF6 and recognition by the cargo receptor p62\/SQSTM1. The combination of the proteasome inhibitor carfilzomib and Mcl1 AUTAC synergistically promoted cell death in both in vitro models, including wild-type and proteasome inhibitor-resistant multiple myeloma and lung cancer cells, and in mouse tumor xenografts. Thus, our work offers a novel strategy for enhancing proteasome inhibitor efficacy by exploiting the adaptive autophagy response. More broadly, our study establishes a framework for amplifying lysosome-mediated targeted protein degradation, with potential applications in cancer therapeutics and beyond.<\/jats:p>","DOI":"10.1038\/s41419-026-08835-6","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:15:36Z","timestamp":1778494536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Proteasome inhibition enhances lysosome-mediated targeted protein degradation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-1643","authenticated-orcid":false,"given":"Ahmed M.","family":"Elshazly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayyerehalsadat","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janakiram","family":"Vangala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyusha P.","family":"Pagare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-1289","authenticated-orcid":false,"given":"Hisashi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-9498","authenticated-orcid":false,"given":"Senthil K.","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"8835_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947\u201359.","journal-title":"Blood"},{"key":"8835_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bjh.15107","volume":"184","author":"HJ Lee","year":"2019","unstructured":"Lee HJ, Badillo M, Romaguera J, Wang M. A phase II study of carfilzomib in the treatment of relapsed\/refractory mantle cell lymphoma. Br J Haematol. 2019;184:460\u20132.","journal-title":"Br J Haematol"},{"key":"8835_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","volume":"44","author":"B Pati\u00f1o-Escobar","year":"2023","unstructured":"Pati\u00f1o-Escobar B, Talbot A, Wiita AP. Overcoming proteasome inhibitor resistance in the immunotherapy era. Trends Pharmacol Sci. 2023;44:507\u201318.","journal-title":"Trends Pharmacol Sci"},{"key":"8835_CR4","doi-asserted-by":"crossref","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12:265.","DOI":"10.3390\/cancers12020265"},{"key":"8835_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/bjh.12452","volume":"162","author":"JJ Gu","year":"2013","unstructured":"Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013;162:657\u201369.","journal-title":"Br J Haematol"},{"key":"8835_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","volume":"24","author":"ES Weyburne","year":"2017","unstructured":"Weyburne ES, Wilkins OM, Sha Z, Williams DA, Pletnev AA, de Bruin G, et al. Inhibition of the proteasome \u03b22 site sensitizes triple-negative breast cancer cells to \u03b25 inhibitors and suppresses Nrf1 activation. Cell Chem Biol. 2017;24:218\u201330.","journal-title":"Cell Chem Biol"},{"key":"8835_CR7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s10637-010-9474-7","volume":"29","author":"MA Shah","year":"2011","unstructured":"Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, et al. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest N drugs. 2011;29:1475\u201381.","journal-title":"Invest N drugs"},{"key":"8835_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/annonc\/mdm600","volume":"19","author":"JE Rosenberg","year":"2008","unstructured":"Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol. 2008;19:946\u201350.","journal-title":"Ann Oncol"},{"key":"8835_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","volume":"72","author":"KP Papadopoulos","year":"2013","unstructured":"Papadopoulos KP, Burris HA 3rd, Gordon M, Lee P, Sausville EA, et al. A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72:861\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"8835_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2009.07.023","volume":"115","author":"C Aghajanian","year":"2009","unstructured":"Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, et al. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;115:215\u201320.","journal-title":"Gynecol Oncol"},{"key":"8835_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/07357900701506573","volume":"25","author":"RH Engel","year":"2007","unstructured":"Engel RH, Brown JA, Von Roenn JH, O\u2019Regan RM, Bergan R, Badve S, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Investig. 2007;25:733\u20137.","journal-title":"Cancer Investig"},{"key":"8835_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","volume":"124","author":"M Ge","year":"2021","unstructured":"Ge M, Qiao Z, Kong Y, Liang H, Sun Y, Lu H, et al. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. Br J Cancer. 2021;124:770\u20136.","journal-title":"Br J Cancer"},{"key":"8835_CR13","doi-asserted-by":"crossref","unstructured":"Ward MA, Vangala JR, Kamber Kaya HE, Byers HA, Hosseini N, Diaz A, et al. Transcription factor Nrf1 regulates proteotoxic stress-induced autophagy. J Cell Biol. 2024;223:e202306150.","DOI":"10.1083\/jcb.202306150"},{"key":"8835_CR14","doi-asserted-by":"crossref","unstructured":"Koizumi S, Irie T, Hirayama S, Sakurai Y, Yashiroda H, Naguro I, et al. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction. eLife. 2016;5:e18357.","DOI":"10.7554\/eLife.18357"},{"key":"8835_CR15","doi-asserted-by":"crossref","unstructured":"Lehrbach NJ, Ruvkun G. Proteasome dysfunction triggers activation of SKN-1A\/Nrf1 by the aspartic protease DDI-1. eLife. 2016;5:e17721.","DOI":"10.7554\/eLife.17721"},{"key":"8835_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/cr.2011.152","volume":"22","author":"E Wirawan","year":"2012","unstructured":"Wirawan E, Berghe TV, Lippens S, Agostinis P, Vandenabeele P. Autophagy: for better or for worse. Cell Res. 2012;22:43\u201361.","journal-title":"Cell Res"},{"key":"8835_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/27694127.2022.2155904","volume":"2","author":"AM Elshazly","year":"2023","unstructured":"Elshazly AM, Wright PA, Xu J, Gewirtz DA. Topoisomerase I poisons-induced autophagy: cytoprotective, cytotoxic or non-protective. Autophagy Rep. 2023;2:1\u201316.","journal-title":"Autophagy Rep"},{"key":"8835_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.08.019","volume":"382","author":"V Jarauta","year":"2016","unstructured":"Jarauta V, Jaime P, Gonzalo O, de Miguel D, Ram\u00edrez-Labrada A, Mart\u00ednez-Lostao L, et al. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo. Cancer Lett. 2016;382:1\u201310.","journal-title":"Cancer Lett"},{"key":"8835_CR19","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.18632\/oncotarget.4530","volume":"6","author":"I Riz","year":"2015","unstructured":"Riz I, Hawley TS, Hawley RG. KLF4-SQSTM1\/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget. 2015;6:14814\u201331.","journal-title":"Oncotarget"},{"key":"8835_CR20","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1182\/blood-2021-146400","volume":"138","author":"SJ Chavda","year":"2021","unstructured":"Chavda SJ, Galas-Filipowicz D, Fitzsimons E, Mikolajczak A, Tooze S, Auner HW, et al. Autophagy blockade disrupts myeloma cell recovery from proteasome inhibition and enhances apoptosis. Blood. 2021;138:1567.","journal-title":"Blood"},{"key":"8835_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09775-y","volume":"22","author":"A Salimi","year":"2022","unstructured":"Salimi A, Schroeder KM, Schemionek-Reinders M, Vieri M, Maletzke S, Gezer D, et al. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK. BMC Cancer. 2022;22:735.","journal-title":"BMC Cancer"},{"key":"8835_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.molcel.2013.10.024","volume":"52","author":"C Ito","year":"2013","unstructured":"Ito C, Saito Y, Nozawa T, Fujii S, Sawa T, Inoue H, et al. Endogenous nitrated nucleotide is a key mediator of autophagy and innate defense against bacteria. Mol Cell. 2013;52:794\u2013804.","journal-title":"Mol Cell"},{"key":"8835_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","volume":"76","author":"D Takahashi","year":"2019","unstructured":"Takahashi D, Moriyama J, Nakamura T, Miki E, Takahashi E, Sato A, et al. AUTACs: cargo-specific degraders using selective autophagy. Mol Cell. 2019;76:797\u2013810.e10.","journal-title":"Mol Cell"},{"key":"8835_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"8835_CR25","doi-asserted-by":"publisher","first-page":"27980","DOI":"10.1073\/pnas.2008885117","volume":"117","author":"E Lucendo","year":"2020","unstructured":"Lucendo E, Sancho M, Lolicato F, Javanainen M, Kulig W, Leiva D, et al. Mcl-1 and Bok transmembrane domains: unexpected players in the modulation of apoptosis. Proc Natl Acad Sci USA. 2020;117:27980\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8835_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699629","volume":"12","author":"O Al-Odat","year":"2021","unstructured":"Al-Odat O, von Suskil M, Chitren R, Elbezanti W, Srivastava S, Budak-Alpddogan T, et al. Mcl-1 inhibition: managing malignancy in multiple myeloma. Front Pharmacol. 2021;12:699629.","journal-title":"Front Pharmacol"},{"key":"8835_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"8835_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-485","volume":"11","author":"W Zhou","year":"2011","unstructured":"Zhou W, Hu J, Tang H, Wang D, Huang X, He C, et al. Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer. 2011;11:485.","journal-title":"BMC Cancer"},{"key":"8835_CR29","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1182\/blood-2004-10-3984","volume":"105","author":"A Nencioni","year":"2005","unstructured":"Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH, et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood. 2005;105:3255\u201362.","journal-title":"Blood"},{"key":"8835_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1436786","volume":"15","author":"OS Al-Odat","year":"2024","unstructured":"Al-Odat OS, Elbezanti WO, Gowda K, Srivastava SK, Amin SG, Jonnalagadda SC, et al. KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis. Front Pharmacol. 2024;15:1436786.","journal-title":"Front Pharmacol"},{"key":"8835_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/15384047.2016.1192086","volume":"17","author":"KG Ponder","year":"2016","unstructured":"Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, et al. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biol Ther. 2016;17:769\u201377.","journal-title":"Cancer Biol Ther"},{"key":"8835_CR32","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1182\/bloodadvances.2020003826","volume":"5","author":"A Bolomsky","year":"2021","unstructured":"Bolomsky A, Miettinen JJ, Malyutina A, Besse A, Huber J, Fellinger S, et al. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv. 2021;5:4125\u201339.","journal-title":"Blood Adv"},{"key":"8835_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Vogler M, K\u00f6se MC, Heckman CA, Ehx G, Ludwig H, et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020;13:173.","journal-title":"J Hematol Oncol"},{"key":"8835_CR34","doi-asserted-by":"publisher","first-page":"12342","DOI":"10.1021\/acs.jmedchem.3c00861","volume":"66","author":"D Takahashi","year":"2023","unstructured":"Takahashi D, Ora T, Sasaki S, Ishii N, Tanaka T, Matsuda T, et al. Second-generation AUTACs for targeted autophagic degradation. J Med Chem. 2023;66:12342\u201372.","journal-title":"J Med Chem"},{"key":"8835_CR35","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1021\/acs.jmedchem.9b00919","volume":"62","author":"Z Wang","year":"2019","unstructured":"Wang Z, He N, Guo Z, Niu C, Song T, Guo Y, et al. Proteolysis targeting chimeras for the selective degradation of Mcl-1\/Bcl-2 derived from nonselective target binding ligands. J Med Chem. 2019;62:8152\u201363.","journal-title":"J Med Chem"},{"key":"8835_CR36","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47:1739\u201349.","journal-title":"J Med Chem"},{"key":"8835_CR37","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47:1750\u20139.","journal-title":"J Med Chem"},{"key":"8835_CR38","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","volume":"63","author":"Z Szlavik","year":"2020","unstructured":"Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J Med Chem. 2020;63:13762\u201395.","journal-title":"J Med Chem"},{"key":"8835_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/cr.2010.149","volume":"21","author":"B Ku","year":"2011","unstructured":"Ku B, Liang C, Jung JU, Oh BH. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011;21:627\u201341.","journal-title":"Cell Res"},{"key":"8835_CR40","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1074\/jbc.M306021200","volume":"279","author":"MK Manion","year":"2004","unstructured":"Manion MK, O\u2019Neill JW, Giedt CD, Kim KM, Zhang KY, Hockenbery DM. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem. 2004;279:2159\u201365.","journal-title":"J Biol Chem"},{"key":"8835_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1750-2187-7-12","volume":"7","author":"VA Stamelos","year":"2012","unstructured":"Stamelos VA, Redman CW, Richardson A. Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal. 2012;7:12.","journal-title":"J Mol Signal"},{"key":"8835_CR42","doi-asserted-by":"publisher","first-page":"e0281463","DOI":"10.1371\/journal.pone.0281463","volume":"18","author":"J Yi","year":"2023","unstructured":"Yi J, Kellner V, Joo H, Chien N, Patel S, Chaban Z, et al. Characterizing the consensus residue specificity and surface of BCL-2 binding to BH3 ligands using the Knob-Socket model. PloS One. 2023;18:e0281463.","journal-title":"PloS One"},{"key":"8835_CR43","doi-asserted-by":"crossref","unstructured":"Kim J, Jin H, Kim J, Cho SY, Moon S, Wang J, et al. Leveraging the fragment molecular orbital and MM-GBSA methods in virtual screening for the discovery of novel non-covalent inhibitors targeting the TEAD lipid binding pocket. Int J Mol Sci. 2024;25:5358.","DOI":"10.3390\/ijms25105358"},{"key":"8835_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00894-009-0454-9","volume":"15","author":"E Durham","year":"2009","unstructured":"Durham E, Dorr B, Woetzel N, Staritzbichler R, Meiler J. Solvent accessible surface area approximations for rapid and accurate protein structure prediction. J Mol Model. 2009;15:1093\u2013108.","journal-title":"J Mol Model"},{"key":"8835_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/cr.2013.168","volume":"24","author":"Y Feng","year":"2014","unstructured":"Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell Res. 2014;24:24\u201341.","journal-title":"Cell Res"},{"key":"8835_CR46","doi-asserted-by":"publisher","first-page":"C781","DOI":"10.1152\/ajpcell.00109.2018","volume":"315","author":"JD Hibshman","year":"2018","unstructured":"Hibshman JD, Leuthner TC, Shoben C, Mello DF, Sherwood DR, Meyer JN, et al. Nonselective autophagy reduces mitochondrial content during starvation in Caenorhabditis elegans. Am J Physiol Cell Physiol. 2018;315:C781\u2013C92.","journal-title":"Am J Physiol Cell Physiol"},{"key":"8835_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.15252\/embj.201489083","volume":"34","author":"H Huang","year":"2015","unstructured":"Huang H, Kawamata T, Horie T, Tsugawa H, Nakayama Y, Ohsumi Y, et al. Bulk RNA degradation by nitrogen starvation-induced autophagy in yeast. EMBO J. 2015;34:154\u201368.","journal-title":"EMBO J"},{"key":"8835_CR48","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14:1435\u201355.","journal-title":"Autophagy"},{"key":"8835_CR49","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1073\/pnas.79.6.1889","volume":"79","author":"PO Seglen","year":"1982","unstructured":"Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic\/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA. 1982;79:1889\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8835_CR50","doi-asserted-by":"publisher","first-page":"28154","DOI":"10.18632\/oncotarget.15962","volume":"8","author":"A Demelash","year":"2017","unstructured":"Demelash A, Pfannenstiel LW, Liu L, Gastman BR. Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence. Oncotarget. 2017;8:28154\u201368.","journal-title":"Oncotarget"},{"key":"8835_CR51","doi-asserted-by":"crossref","unstructured":"Chang SH, Chuang KC, Li ZY, Chang MC, Liu KT, Hsu CS, et al. The protective effects of Mcl-1 on mitochondrial damage and oxidative stress in imiquimod-induced cancer cell death. Cancers. 2024;16:3060.","DOI":"10.3390\/cancers16173060"},{"key":"8835_CR52","doi-asserted-by":"crossref","unstructured":"Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007;26:1749-60-60.","DOI":"10.1038\/sj.emboj.7601623"},{"key":"8835_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119041","volume":"1868","author":"M Redza-Dutordoir","year":"2021","unstructured":"Redza-Dutordoir M, Averill-Bates DA. Interactions between reactive oxygen species and autophagy: special issue: death mechanisms in cellular homeostasis. Biochim Biophys Acta Mol Cell Res. 2021;1868:119041.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"8835_CR54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/emboj.2010.327","volume":"30","author":"M Germain","year":"2011","unstructured":"Germain M, Nguyen AP, Le Grand JN, Arbour N, Vanderluit JL, Park DS, et al. MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J. 2011;30:395\u2013407.","journal-title":"EMBO J"},{"key":"8835_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6637","volume":"5","author":"M Elgendy","year":"2014","unstructured":"Elgendy M, Ciro M, Abdel-Aziz AK, Belmonte G, Zuffo RD, Mercurio C, et al. Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nat Commun. 2014;5:5637.","journal-title":"Nat Commun"},{"key":"8835_CR56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1042\/BJ20130282","volume":"454","author":"M Halasi","year":"2013","unstructured":"Halasi M, Wang M, Chavan TS, Gaponenko V, Hay N, Gartel AL. ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. Biochem J. 2013;454:201\u20138.","journal-title":"Biochem J"},{"key":"8835_CR57","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.1128\/MCB.24.18.8055-8068.2004","volume":"24","author":"ML Seibenhener","year":"2004","unstructured":"Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1\/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol. 2004;24:8055\u201368.","journal-title":"Mol Cell Biol"},{"key":"8835_CR58","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798308","volume":"37","author":"G Zaffagnini","year":"2018","unstructured":"Zaffagnini G, Savova A, Danieli A, Romanov J, Tremel S, Ebner M, et al. p62 filaments capture and present ubiquitinated cargos for autophagy. EMBO J. 2018;37:e98308.","journal-title":"EMBO J"},{"key":"8835_CR59","doi-asserted-by":"publisher","first-page":"22847","DOI":"10.1074\/jbc.M802182200","volume":"283","author":"Y Ichimura","year":"2008","unstructured":"Ichimura Y, Kumanomidou T, Sou Y-s, Mizushima T, Ezaki J, Ueno T, et al. Structural basis for sorting mechanism of p62 in selective autophagy*. J Biol Chem. 2008;283:22847\u201357.","journal-title":"J Biol Chem"},{"key":"8835_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/832704","volume":"2014","author":"M Lippai","year":"2014","unstructured":"Lippai M, L\u0151w P. The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. BioMed Res Int. 2014;2014:832704.","journal-title":"BioMed Res Int"},{"key":"8835_CR61","doi-asserted-by":"publisher","first-page":"e1004458","DOI":"10.1371\/journal.ppat.1004458","volume":"10","author":"YB Choi","year":"2014","unstructured":"Choi YB, Harhaj EW. HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. PLoS Pathog. 2014;10:e1004458.","journal-title":"PLoS Pathog"},{"key":"8835_CR62","doi-asserted-by":"publisher","first-page":"13191","DOI":"10.1074\/jbc.RA118.002649","volume":"293","author":"JK Brenke","year":"2018","unstructured":"Brenke JK, Popowicz GM, Schorpp K, Rothenaigner I, Roesner M, Meininger I, et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018;293:13191\u2013203.","journal-title":"J Biol Chem"},{"key":"8835_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.54","volume":"5","author":"J Cheng","year":"2014","unstructured":"Cheng J, Fan YH, Xu X, Zhang H, Dou J, Tang Y, et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014;5:e1079.","journal-title":"Cell Death Dis"},{"key":"8835_CR64","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1073\/pnas.1100844108","volume":"108","author":"L Shang","year":"2011","unstructured":"Shang L, Chen S, Du F, Li S, Zhao L, Wang X. Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK. Proc Natl Acad Sci USA. 2011;108:4788\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8835_CR65","first-page":"237","volume":"5","author":"K Fostier","year":"2012","unstructured":"Fostier K, De Becker A, Schots R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. OncoTargets Ther. 2012;5:237\u201344.","journal-title":"OncoTargets Ther"},{"key":"8835_CR66","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4161\/auto.22185","volume":"8","author":"Y Zang","year":"2012","unstructured":"Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, et al. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012;8:1873\u20134.","journal-title":"Autophagy"},{"key":"8835_CR67","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4161\/auto.4600","volume":"3","author":"N Mizushima","year":"2007","unstructured":"Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542\u20135.","journal-title":"Autophagy"},{"key":"8835_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","volume":"38","author":"SK Radhakrishnan","year":"2010","unstructured":"Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010;38:17\u201328.","journal-title":"Mol Cell"},{"key":"8835_CR69","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01856","volume":"3","author":"SK Radhakrishnan","year":"2014","unstructured":"Radhakrishnan SK, den Besten W, Deshaies RJ. p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife. 2014;3:e01856.","journal-title":"eLife"},{"key":"8835_CR70","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1074\/jbc.RA118.006290","volume":"294","author":"JR Vangala","year":"2019","unstructured":"Vangala JR, Radhakrishnan SK. Nrf1-mediated transcriptional regulation of the proteasome requires a functional TIP60 complex. J Biol Chem. 2019;294:2036\u201345.","journal-title":"J Biol Chem"},{"key":"8835_CR71","doi-asserted-by":"publisher","first-page":"R834","DOI":"10.1016\/j.cub.2016.08.008","volume":"26","author":"JR Vangala","year":"2016","unstructured":"Vangala JR, Sotzny F, Kr\u00fcger E, Deshaies RJ, Radhakrishnan SK. Nrf1 can be processed and activated in a proteasome-independent manner. Curr Biol CB. 2016;26:R834\u2013r5.","journal-title":"Curr Biol CB"},{"key":"8835_CR72","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1631\/jzus.B2100804","volume":"23","author":"Z Bai","year":"2022","unstructured":"Bai Z, Peng Y, Ye X, Liu Z, Li Y, Ma L. Autophagy and cancer treatment: four functional forms of autophagy and their therapeutic applications. J Zhejiang Univ Sci B. 2022;23:89\u2013101.","journal-title":"J Zhejiang Univ Sci B"},{"key":"8835_CR73","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1158\/0008-5472.CAN-13-2966","volume":"74","author":"DA Gewirtz","year":"2014","unstructured":"Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014;74:647\u201351.","journal-title":"Cancer Res"},{"key":"8835_CR74","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.3390\/cancers16172989","volume":"16","author":"AM Elshazly","year":"2024","unstructured":"Elshazly AM, Xu J, Melhem N, Abdulnaby A, Elzahed AA, Saleh T, et al. Is autophagy targeting a valid adjuvant strategy in conjunction with tyrosine kinase inhibitors?. Cancers. 2024;16:2989.","journal-title":"Cancers"},{"key":"8835_CR75","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/10428194.2023.2200876","volume":"64","author":"P Torka","year":"2023","unstructured":"Torka P, Russell T, Mavis C, Gu J, Ghione P, Barth M, et al. AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas. Leuk lymphoma. 2023;64:1175\u201385.","journal-title":"Leuk lymphoma"},{"key":"8835_CR76","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/jphp.13240","volume":"72","author":"KY Wong","year":"2020","unstructured":"Wong KY, Chim CS. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol. 2020;72:728\u201337.","journal-title":"J Pharm Pharmacol"},{"key":"8835_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1394393","volume":"14","author":"D Galas-Filipowicz","year":"2024","unstructured":"Galas-Filipowicz D, Chavda SJ, Gong JN, Huang DCS, Khwaja A, Yong K. Co-operation of MCL-1 and BCL-X(L) anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity. Front Oncol. 2024;14:1394393.","journal-title":"Front Oncol"},{"key":"8835_CR78","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8:1582\u201397.","journal-title":"Cancer Discov"},{"key":"8835_CR79","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"8835_CR80","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.1103966","volume":"306","author":"I Nakagawa","year":"2004","unstructured":"Nakagawa I, Amano A, Mizushima N, Yamamoto A, Yamaguchi H, Kamimoto T, et al. Autophagy defends cells against invading group A Streptococcus. Science. 2004;306:1037\u201340.","journal-title":"Science"},{"key":"8835_CR81","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nchembio.2007.33","volume":"3","author":"T Sawa","year":"2007","unstructured":"Sawa T, Zaki MH, Okamoto T, Akuta T, Tokutomi Y, Kim-Mitsuyama S, et al. Protein S-guanylation by the biological signal 8-nitroguanosine 3\u2032, 5\u2032-cyclic monophosphate. Nat Chem Biol. 2007;3:727\u201335.","journal-title":"Nat Chem Biol"},{"key":"8835_CR82","doi-asserted-by":"publisher","first-page":"e1006444","DOI":"10.1371\/journal.ppat.1006444","volume":"13","author":"S-L Lu","year":"2017","unstructured":"Lu S-L, Kawabata T, Cheng Y-L, Omori H, Hamasaki M, Kusaba T, et al. Endothelial cells are intrinsically defective in xenophagy of Streptococcus pyogenes. PLoS Pathog. 2017;13:e1006444.","journal-title":"PLoS Pathog"},{"key":"8835_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.18","volume":"4","author":"WT Tai","year":"2013","unstructured":"Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 2013;4:e485.","journal-title":"Cell Death Dis"},{"key":"8835_CR84","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1038\/cddis.2013.155","volume":"4","author":"A Sharma","year":"2013","unstructured":"Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis. 2013;4:e628.","journal-title":"Cell Death Dis"},{"key":"8835_CR85","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","volume":"16","author":"D Takahashi","year":"2020","unstructured":"Takahashi D, Arimoto H. Targeting selective autophagy by AUTAC degraders. Autophagy. 2020;16:765\u20136.","journal-title":"Autophagy"},{"key":"8835_CR86","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202152584","volume":"22","author":"A Yamada","year":"2021","unstructured":"Yamada A, Hikichi M, Nozawa T, Nakagawa I. FBXO2\/SCF ubiquitin ligase complex directs xenophagy through recognizing bacterial surface glycan. EMBO Rep. 2021;22:e52584.","journal-title":"EMBO Rep"},{"key":"8835_CR87","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27:405\u201319.","journal-title":"Cell Death Differ"},{"key":"8835_CR88","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1111\/febs.16136","volume":"289","author":"M Sancho","year":"2022","unstructured":"Sancho M, Leiva D, Lucendo E, Orz\u00e1ez M. Understanding MCL1: from cellular function and regulation to pharmacological inhibition. FEBS J. 2022;289:6209\u201334.","journal-title":"FEBS J"},{"key":"8835_CR89","first-page":"33","volume":"109","author":"GLQ Tang","year":"2024","unstructured":"Tang GLQ, Lai JXH, Pervaiz S. Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches. Haematologica. 2024;109:33\u201343.","journal-title":"Haematologica"},{"key":"8835_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01204-0","volume":"8","author":"L Cao","year":"2022","unstructured":"Cao L, Liu X, Zheng B, Xing C, Liu J. Role of K63-linked ubiquitination in cancer. Cell Death Discov. 2022;8:410.","journal-title":"Cell Death Discov"},{"key":"8835_CR91","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41418-021-00922-9","volume":"29","author":"JZ Roberts","year":"2022","unstructured":"Roberts JZ, Crawford N, Longley DB. The role of ubiquitination in apoptosis and necroptosis. Cell Death Differ. 2022;29:272\u201384.","journal-title":"Cell Death Differ"},{"key":"8835_CR92","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fonc.2012.00005","volume":"2","author":"G Wang","year":"2012","unstructured":"Wang G, Gao Y, Li L, Jin G, Cai Z, Chao JI, et al. K63-linked ubiquitination in kinase activation and cancer. Front Oncol. 2012;2:5.","journal-title":"Front Oncol"},{"key":"8835_CR93","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.18632\/aging.102710","volume":"12","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Zhu X, Yin R, Liu T, Yang S, Zhou L, et al. K63 ubiquitin chains target NLRP3 inflammasome for autophagic degradation in ox-LDL-stimulated THP-1 macrophages. Aging. 2020;12:1747\u201359.","journal-title":"Aging"},{"key":"8835_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78845-7","volume":"10","author":"TJC Richard","year":"2020","unstructured":"Richard TJC, Herzog LK, Vornberger J, Rahmanto AS, Sangfelt O, Salomons FA, et al. K63-linked ubiquitylation induces global sequestration of mitochondria. Sci Rep. 2020;10:22334.","journal-title":"Sci Rep"},{"key":"8835_CR95","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.it.2021.12.005","volume":"43","author":"C Madiraju","year":"2022","unstructured":"Madiraju C, Novack JP, Reed JC, Matsuzawa SI. K63 ubiquitination in immune signaling. Trends Immunol. 2022;43:148\u201362.","journal-title":"Trends Immunol"},{"key":"8835_CR96","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nsmb.3052","volume":"22","author":"E Branigan","year":"2015","unstructured":"Branigan E, Plechanovov\u00e1 A, Jaffray EG, Naismith JH, Hay RT. Structural basis for the RING-catalyzed synthesis of K63-linked ubiquitin chains. Nat Struct Mol Biol. 2015;22:597\u2013602.","journal-title":"Nat Struct Mol Biol"},{"key":"8835_CR97","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s42977-022-00117-4","volume":"73","author":"A D\u00f3sa","year":"2022","unstructured":"D\u00f3sa A, Csizmadia T. The role of K63-linked polyubiquitin in several types of autophagy. Biol Futur. 2022;73:137\u201348.","journal-title":"Biol Futur"},{"key":"8835_CR98","doi-asserted-by":"crossref","unstructured":"Elshazly AM, Gewirtz DA. Is autophagy inhibition in combination with temozolomide a therapeutically viable strategy? Cells. 2023;12:535.","DOI":"10.3390\/cells12040535"},{"key":"8835_CR99","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-017-0048-x","volume":"4","author":"C Manzo","year":"2017","unstructured":"Manzo C, Gareri P, Castagna A. Psychomotor agitation following treatment with hydroxychloroquine. Drug Saf Case Rep. 2017;4:6.","journal-title":"Drug Saf Case Rep"},{"key":"8835_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.633112","volume":"12","author":"H Xu","year":"2021","unstructured":"Xu H, Zhang XY, Wang WW, Wang J. Hydroxychloroquine increased anxiety-like behaviors and disrupted the expression of some related genes in the mouse brain. Front Pharmacol. 2021;12:633112.","journal-title":"Front Pharmacol"},{"key":"8835_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.616075","volume":"11","author":"E Naddaf","year":"2020","unstructured":"Naddaf E, Paul P, AbouEzzeddine OF. Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes. Front Neurol. 2020;11:616075.","journal-title":"Front Neurol"},{"key":"8835_CR102","doi-asserted-by":"crossref","unstructured":"Benjamin, Buck Eric, Kellett Daniel, Addison Ajay, Vallakati (2022) Carfilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS) Journal of the Saudi Heart Association 34(3) 134-141 10.37616\/2212-5043.1311","DOI":"10.37616\/2212-5043.1311"},{"key":"8835_CR103","doi-asserted-by":"crossref","unstructured":"Adam J., Waxman Suparna, Clasen Wei-Ting, Hwang Alfred, Garfall Dan T., Vogl Joseph, Carver Rupal, O\u2019Quinn Adam D., Cohen Edward A., Stadtmauer Bonnie, Ky Brendan M., Weiss (2018) Carfilzomib-Associated Cardiovascular Adverse Events JAMA Oncology 4(3) e174519-10.1001\/jamaoncol.2017.4519","DOI":"10.1001\/jamaoncol.2017.4519"},{"key":"8835_CR104","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/2767-9764.CRC-23-0637","volume":"4","author":"KK Chougoni","year":"2024","unstructured":"Chougoni KK, Neely V, Ding B, Oduah E, Lam VT, Hu B, et al. Oncogenic mutant p53 sensitizes non\u2013small cell lung cancer cells to proteasome inhibition via oxidative stress\u2013dependent induction of mitochondrial apoptosis. Cancer Res Commun. 2024;4:2685\u201398.","journal-title":"Cancer Res Commun"},{"key":"8835_CR105","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s13402-023-00817-6","volume":"46","author":"L Li","year":"2023","unstructured":"Li L, Hu X, Nkwocha J, Sharma K, Kmieciak M, Mann H, et al. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells. Cell Oncol. 2023;46:1369\u201380.","journal-title":"Cell Oncol"},{"key":"8835_CR106","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1128\/MCB.01383-13","volume":"34","author":"S Chen","year":"2014","unstructured":"Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, et al. Targeting SQSTM1\/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK\/Bik. Mol Cell Biol. 2014;34:3435\u201349.","journal-title":"Mol Cell Biol"},{"key":"8835_CR107","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jso.2930310402","volume":"31","author":"DM Euhus","year":"1986","unstructured":"Euhus DM, Hudd C, Laregina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986;31:229\u201334.","journal-title":"J Surg Oncol"},{"key":"8835_CR108","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinforma"},{"key":"8835_CR109","doi-asserted-by":"crossref","unstructured":"Strober W. Trypan blue exclusion test of cell viability. Curr Protocols Immunol. 2015;111:A3.B.1\u2013a3.B.","DOI":"10.1002\/0471142735.ima03bs111"},{"key":"8835_CR110","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27:221\u201334.","journal-title":"J Comput Aided Mol Des"},{"key":"8835_CR111","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1021\/acs.jctc.3c00044","volume":"19","author":"RC Johnston","year":"2023","unstructured":"Johnston RC, Yao K, Kaplan Z, Chelliah M, Leswing K, Seekins S, et al. Epik: pK(a) and protonation state prediction through machine learning. J Chem Theory Comput. 2023;19:2380\u20138.","journal-title":"J Chem Theory Comput"},{"key":"8835_CR112","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J Chem theory Comput. 2021;17:4291\u2013300.","journal-title":"J Chem theory Comput"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08835-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:23:33Z","timestamp":1783052613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08835-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8835"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08835-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.31.634950","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}